Abstract Details

Title The Cost Burden of Multiple Sclerosis in the United States (US): A Systematic Review of the Literature

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 207

Objective

Background BACKGROUND: MS places a substantial burden on patients and on society as a whole. In addition to the direct cost of intensive medical and pharmacologic treatment, there are large indirect costs associated with patients leaving the workforce prematurely.

Design/Methods DESIGN/METHODS: A search of English language literature published (2007-2012) in PubMed/Embase was performed, using the term "multiple sclerosis," plus the medical subject heading "healthcare costs." Included articles were primary studies, with MS cost figures that could be converted to per patient/year values. Additional articles were identified from a reference list review. Data from the included studies were abstracted into a series of Excel spreadsheets and analyzed.

Results RESULTS: Fifteen studies (of 172) met the inclusion/exclusion criteria. Eight articles presented only direct cost calculations, while the remaining seven presented estimates of total cost, broken down into direct and indirect. Total all-cause healthcare costs for MS from studies that included both direct and indirect costs ranged from $7,480 to $43,796 per person/year. On average, direct costs comprised 77% (range 64-91%) of total costs. Prescription medication accounted for about half of direct medical costs. On average, indirect costs made up 23% (9-36%) of total costs. When compared with direct all-cause medical costs of other chronic conditions reported in the literature such as diabetes, COPD and coronary artery disease, MS ranked among the most costly, second only to congestive heart failure.

Conclusions CONCLUSIONS: MS is a costly chronic disease, with high average direct and indirect costs per patient/year. Further research is needed to better understand: costs by MS type, costs associated with increasing disability and early retirement, and the potential impact of new treatments expected to launch in the coming years.

Authors/Disclosures
PRESENTER	No disclosure on file
Stanley Rane, PhD (Novartis Pharmaceuticals)	No disclosure on file
Kathleen Villa	No disclosure on file
Herbert Schreiber	Herbert Schreiber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Herbert Schreiber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis . Herbert Schreiber has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Herbert Schreiber has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Herbert Schreiber has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Herbert Schreiber has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall. Herbert Schreiber has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis . Herbert Schreiber has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Herbert Schreiber has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Herbert Schreiber has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.

��ɫ��

��ɫ��